Skip to main content

Table 2 Results of the interrupted time series analysis for initiation of osteoporosis investigations and treatments, combined across the three sites*

From: A knowledge translation tool improved osteoporosis disease management in primary care: an interrupted time series analysis

Outcomes Mean of proportions across the three sites (SD) % Increase Pvalue
Baseline Intervention
Initiation of BMD testing 2.79 (1.27) 6.15 (2.24) 3.4 <0.001
  95% CI 1.86 to 3.74 3.38 to 8.42 2.03 to 4.68
Initiation of any osteoporosis medication 0.42 (0.36) 0.87 (0.66) 0.5 0.006
  95% CI 0 to 1.13 0 to 2.16 0.15 to 0.85
Initiation of calcium + vitamin D 0.70 (0.56) 1.58 (0.95) 0.9 <0.001
  95% CI 0 to 1.80 0 to 3.44 0.39 to 1.41
Initiation of any nutritional supplement (calcium or vitamin D) 0.97 (0.71) 2.13 (1.28) 1.2 0.001
  95% CI 0 to 2.36 0 to 4.64 0.49 to 1.91
  1. *BMD, bone mineral density; SD, standard deviation.
  2. From autoregressive integrated moving-average (ARIMA) model. Intercept only model is fitted since the slopes are not significantly different from zero.
  3. The following osteoporosis medications were considered: any bisphosphonate (alendronate, etidronate, risedronate, zoledronic acid), any selective estrogen receptor modulator (e.g., raloxifene), nasal calcitonin, parathyroid hormone, and hormone replacement therapy.